Advanced

Therapeutic cleavage of IgG: new avenues for treating inflammation.

Nandakumar, Kutty Selva and Holmdahl, Rikard LU (2008) In Trends in Immunology 29. p.173-178
Abstract
Autoantibodies developing in humans contribute to the pathogenesis of several diseases, and injected therapeutic antibodies can also trigger adverse side effects. An efficient and rapid elimination of these antibodies are therefore critically needed. Antibody removal by plasmapheresis and immunoadsorption are commonly used methods but have their own limitations. Bacterial enzymes that can cleave IgG molecules or remove carbohydrate moieties to ameliorate their immunogenicity or effector functions in vivo offer new avenues for drug development. Recent discoveries highlight the possibility of cleaving or modifying IgG in vivo by injection of enzymes. Such an approach opens up new therapeutic possibilities not only for the control of... (More)
Autoantibodies developing in humans contribute to the pathogenesis of several diseases, and injected therapeutic antibodies can also trigger adverse side effects. An efficient and rapid elimination of these antibodies are therefore critically needed. Antibody removal by plasmapheresis and immunoadsorption are commonly used methods but have their own limitations. Bacterial enzymes that can cleave IgG molecules or remove carbohydrate moieties to ameliorate their immunogenicity or effector functions in vivo offer new avenues for drug development. Recent discoveries highlight the possibility of cleaving or modifying IgG in vivo by injection of enzymes. Such an approach opens up new therapeutic possibilities not only for the control of pathogenic antibody-mediated inflammatory diseases but also allograft rejection or the treatment of side-effects of 'biologicals' such as monoclonal antibodies. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Trends in Immunology
volume
29
pages
173 - 178
publisher
Elsevier
external identifiers
  • pmid:18328782
  • wos:000255469300022
  • scopus:41349090782
ISSN
1471-4981
DOI
10.1016/j.it.2008.01.007
language
English
LU publication?
yes
id
76dbf97b-7ff2-4db4-8638-cae02fdb98db (old id 1052713)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18328782?dopt=Abstract
date added to LUP
2008-04-02 12:08:05
date last changed
2017-01-01 07:34:57
@article{76dbf97b-7ff2-4db4-8638-cae02fdb98db,
  abstract     = {Autoantibodies developing in humans contribute to the pathogenesis of several diseases, and injected therapeutic antibodies can also trigger adverse side effects. An efficient and rapid elimination of these antibodies are therefore critically needed. Antibody removal by plasmapheresis and immunoadsorption are commonly used methods but have their own limitations. Bacterial enzymes that can cleave IgG molecules or remove carbohydrate moieties to ameliorate their immunogenicity or effector functions in vivo offer new avenues for drug development. Recent discoveries highlight the possibility of cleaving or modifying IgG in vivo by injection of enzymes. Such an approach opens up new therapeutic possibilities not only for the control of pathogenic antibody-mediated inflammatory diseases but also allograft rejection or the treatment of side-effects of 'biologicals' such as monoclonal antibodies.},
  author       = {Nandakumar, Kutty Selva and Holmdahl, Rikard},
  issn         = {1471-4981},
  language     = {eng},
  pages        = {173--178},
  publisher    = {Elsevier},
  series       = {Trends in Immunology},
  title        = {Therapeutic cleavage of IgG: new avenues for treating inflammation.},
  url          = {http://dx.doi.org/10.1016/j.it.2008.01.007},
  volume       = {29},
  year         = {2008},
}